International Journal of Research in Medical Sciences, Год журнала: 2025, Номер 13(2), С. 906 - 910
Опубликована: Янв. 30, 2025
With few available treatments and a dismal prognosis, pancreatic cancer is among the most aggressive deadly cancers. Immunotherapy has become potential strategy to increase anti-tumor immunity, especially vaccines. GVAX, an allogeneic vaccine employing granulocyte-macrophage colony-stimulating factor as immune adjuvant, emerged promising therapeutic enhance immunity. Initial trials of GVAX showed mixed results, with some patients exhibiting responses prolonged survival. Subsequent studies explored combinations chemotherapy checkpoint inhibitors, such ipilimumab nivolumab. While these demonstrated immunological effects improved clinical outcomes in cases, overall survival benefit been inconsistent, advanced disease stages. Recent are further investigating optimal dosing regimens maximize efficacy GVAX-based immunotherapy cancer. In conclusion, holds promise component for However, research needed optimize its use combination other therapies identify patient populations that may from this approach.
Язык: Английский